thyssenkrupp nucera doubles nine‑month order intake, halts SOEC mass‑production plan

Order intake and major contracts

Order intake rose to €81m in Q3 (+29%) and to €471m in the first nine months (+96%). In gH2 the company won Moeve’s 300‑MW new‑build green hydrogen plant, including a long‑term service package with digital twins, intelligent load management and operational simulations.

Segment performance

Group sales were €145m in Q3 (prior year €184m) and €354m for nine months (prior year €663m). Chlor‑Alkali (CA) showed strength: Q3 order intake €78m (+57%), Q3 sales €109m and Q3 EBIT €15m; nine‑month CA order intake €288m and EBIT €38m. Green Hydrogen (gH2) remained volatile: Q3 order intake €3m, Q3 sales €36m and EBIT €‑17m; nine‑month gH2 order intake €184m, nine‑month sales €80m and EBIT €‑107m.

SOEC strategy change

After a strategic review, the company will no longer pursue building its own SOEC mass‑production capacity, citing limited market readiness and investment economics. The decision causes approximately €30m of one‑time negative EBIT effects from impairments of pilot plant and capitalized development costs.

Balance sheet and cash

Net financial assets were €627m at June 30, 2026; order backlog €638m. Free cash flow for nine months was €‑26m and headcount stood at 1,076.

Outlook update

Management now expects FY25/26 order intake of €550–670m (previously €550–850m), Group sales €450–500m (previously €450–550m) and Group EBIT €‑105m to €‑75m (previously €‑80m to €‑30m). For gH2 sales the new range is €100–130m with EBIT €‑155m to €‑135m; CA outlook remains sales €320–400m and EBIT €45–65m.